Podcasts Science Life Sciences Frankly Speaking About Family Medicine New Benefits Give SGLT2 Inhibitors Their Turn to Shine - Frankly Speaking Ep 376

New Benefits Give SGLT2 Inhibitors Their Turn to Shine - Frankly Speaking Ep 376

Published: April 15, 2024, 12:30 a.m.

Credits: 0.25 AMA PRA Category 1 Credit\u2122\xa0CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-376\nOverview: While GLP-1 agents are center stage in the medical and lay press, drugs in the class of sodium-glucose cotransporter 2 inhibitors (SGLT2is) are also quite remarkable at improving a variety of health endpoints. This episode provides an overview of studies supporting the use of SGLT2is to improve patient outcomes.\nEpisode resource links:\nDM/HF: \xa0Age Ageing 2024 Jan 2;53(1):afad254. doi: 10.1093/ageing/afad254\nKidney stones: JAMA Intern Med. 2024 Jan 29:e237660. doi: 10.1001/jamainternmed.2023.7660\nGuest: Susan Feeney, DNP, FNP-BC, NP-C\xa0Music Credit: Richard Onorato